PLATINUM INVESTMENT MANAGEMENT LTD
Position in SKYE — Skye Bioscience, Inc.
CIK 1256071
SYDNEY AUSTRALIA 2000, C3
Position in SKYE
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$143,353
-$31,468 QoQ
Shares Held
233,095
0.0% QoQ
Ownership
0.663%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SKYE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026PLATINUM INVESTMENT MANAGEMENT LTD holds $70,718,725 across 29 Biotechnology names. SKYE ranks #29 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TERN |
Terns Pharmaceuticals, Inc.
|
110,734 | $5,837,896 | |
| 2 | CNTA |
Centessa Pharmaceuticals plc
|
137,741 | $5,471,072 | |
| 3 | APGE |
Apogee Therapeutics, Inc.
|
58,314 | $4,908,289 | |
| 4 | VERA |
Vera Therapeutics, Inc.
|
113,687 | $4,573,628 | |
| 5 | IMVT |
Immunovant, Inc.
|
181,774 | $4,515,266 | |
| 6 | COGT |
Cogent Biosciences, Inc.
|
112,066 | $4,313,420 | |
| 7 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
64,752 | $4,059,950 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
49,269 | $3,658,715 |
All Filings in SKYE
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $143,353 | 233,095 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $174,821 | 233,095 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $916,063 | 233,095 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $1,226,077 | 293,320 | Shares | Sole | 2025-07-21 | |
| 2025-03-31 | $466,378 | 293,320 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $1,228,350 | 434,046 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $1,897,128 | 485,199 | Shares | Sole | 2024-11-08 | |
| No filing history on record for this holder in this stock. | ||||||